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Introduction {#ehf212500-sec-0004}
============

Heart failure (HF) is a major public health issue worldwide. Recent guidelines on acute and chronic HF classified them into three groups according to left ventricular ejection fraction (LVEF): HF with reduced EF (HFrEF; EF \<40%), HF with mid‐range EF (HFmrEF; 40% ≤ EF \< 50%), and HF with preserved EF (HFpEF; 50% ≤ EF). Although treatment strategies for HFrEF have significantly improved over the past two decades,[1](#ehf212500-bib-0001){ref-type="ref"}, [2](#ehf212500-bib-0002){ref-type="ref"}, [3](#ehf212500-bib-0003){ref-type="ref"} its prognosis remains poor. As well, previous randomized clinical trials in patients with HFpEF have failed to show a beneficial effect of the drug therapy being trialled. Of note, patients with HFmrEF were not included in some of these earlier clinical trials.

To further improve the treatment strategy for all types of HF, the treatable risk factors for HF should be investigated. Although hypertension is one of the well‐known major risk factors for the development of HF, once HF develops, the relationship between systolic blood pressure (SBP) and the recurrence of HF is unclear. Several earlier studies have reported that lower SBP at admission is associated with a higher incidence rate of cardiovascular events, including unexpected HF admission.[4](#ehf212500-bib-0004){ref-type="ref"}, [5](#ehf212500-bib-0005){ref-type="ref"}, [6](#ehf212500-bib-0006){ref-type="ref"} However, none of the guidelines for the management of hypertension or HF have provided a target SBP for any of the HF types.

Ambulatory BP monitoring (ABPM) is a useful tool to investigate the circadian rhythm of BP in individuals on no medication and to assess the effect of antihypertensive drugs on 24 h BP control in patients undergoing treatment. Recently, serial out‐of‐office ABPM was recommended for better management of hypertension.[7](#ehf212500-bib-0007){ref-type="ref"} ABPM can also provide novel information on risk factors for cardiovascular death and HF. Several earlier reports showed that abnormal variations in the 24 h BP, such as the morning surge and nocturnal increase in SBP, are important predictors of cardiovascular events in the general population and in patients with hypertension, irrespective of BP treatment.[8](#ehf212500-bib-0008){ref-type="ref"}, [9](#ehf212500-bib-0009){ref-type="ref"}, [10](#ehf212500-bib-0010){ref-type="ref"}, [11](#ehf212500-bib-0011){ref-type="ref"}, [12](#ehf212500-bib-0012){ref-type="ref"}, [13](#ehf212500-bib-0013){ref-type="ref"} However, there have been only a few reports on ABPM measurements in patients with HF.[14](#ehf212500-bib-0014){ref-type="ref"}, [15](#ehf212500-bib-0015){ref-type="ref"}, [16](#ehf212500-bib-0016){ref-type="ref"} Recently, Komori *et al*.[16](#ehf212500-bib-0016){ref-type="ref"} reported that the riser pattern of SBP is associated with worse prognosis among patients with HFpEF but not those with HFrEF. In this study, however, HFrEF was defined as EF ≤50%, which includes HFrEF (EF \<40%) and HFmrEF (40% ≤ EF \< 50%). Considering the limitation of current evidence regarding the relationship between BP and the three types of HF, our aim in this study was to investigated the prognostic impact of 24 h BP variation for the three types of HF (HFrEF, HFmrEF, and HFpEF), using the data from the Nara Registry and Analyses for Heart Failure cohort study (NARA‐HF study).[17](#ehf212500-bib-0017){ref-type="ref"}, [18](#ehf212500-bib-0018){ref-type="ref"}, [19](#ehf212500-bib-0019){ref-type="ref"}, [20](#ehf212500-bib-0020){ref-type="ref"}, [21](#ehf212500-bib-0021){ref-type="ref"}, [22](#ehf212500-bib-0022){ref-type="ref"}

Methods {#ehf212500-sec-0005}
=======

Study population and data collection {#ehf212500-sec-0006}
------------------------------------

The NARA‐HF was designed as a dynamic cohort study.[17](#ehf212500-bib-0017){ref-type="ref"}, [18](#ehf212500-bib-0018){ref-type="ref"}, [19](#ehf212500-bib-0019){ref-type="ref"}, [20](#ehf212500-bib-0020){ref-type="ref"}, [21](#ehf212500-bib-0021){ref-type="ref"}, [22](#ehf212500-bib-0022){ref-type="ref"} The study recruited 1074 consecutive patients who were emergently admitted to our department or the coronary care unit at our hospital with documented acute decompensated HF (ADHF; either acute new‐onset or acute‐on‐chronic HF) between January 2007 and December 2016. The diagnosis of HF was based on the Framingham Criteria.[23](#ehf212500-bib-0023){ref-type="ref"} The study population included patients with HFrEF, HFmrEF, and HFpEF. Patients with acute myocardial infarction, acute myocarditis, and acute HF with acute pulmonary embolism were excluded.

The ABPM measurements started in April 2011 as part of the NARA‐HF study, and 369 of 1074 patients had ABPM performed immediately before discharge. Among them, 44 patients were excluded from the analysis because of insufficient data. Consequently, we analysed the data of 325 patients (124 with HFrEF, 71 with HFmrEF, and 130 with HFpEF). For each patient, baseline data collected included age, sex, body mass index (BMI), HF aetiology, medical history, vital signs, laboratory and echocardiographic data, and medications on admission and at discharge.

The study was approved by the Ethics Committee of Nara Medical University, and written informed consent was obtained from all patients in accordance with the Declaration of Helsinki\'s Ethical Principles for Medical Research Involving Human Subjects.

Blood pressure measurement {#ehf212500-sec-0007}
--------------------------

Ambulatory blood pressure monitoring was performed immediately before discharge by an automatic system using electrical cuff inflation (FB‐270; Fukuda Denshi Co., Tokyo, Japan), which recorded SBP and diastolic BP (DBP) (by the oscillometric method) and pulse rate every 30 min during daytime (6 a.m. to 9:59 p.m.) and every 60 min during night‐time (10 p.m. to 5:59 a.m.). BP measurements were expressed in millimetres of mercury (mmHg). BP measurement was performed on the side opposite the dominant arm in this study.

The 24 h BP was defined as the average value of BP measured over an entire day. We defined the awake BP as the average value of BP measurements from 7 a.m. to 8:30 p.m. and the sleep‐time BP as the average value of BP measurements from 10 p.m. to 5 a.m., as awake‐time was 6 a.m. and lights‐out time was 9 p.m. at our hospital. A minimum of 20 valid awake readings and five valid sleep readings were made to define the awake and sleep‐time BP, but all patients had significantly more valid readings. Nocturnal hypertension was defined as a sleep‐time SBP ≥120 mmHg and/or sleep‐time DBP ≥70 mmHg, based on the 2014 guidelines for the management of hypertension published by The Japanese Society of Hypertension.[7](#ehf212500-bib-0007){ref-type="ref"} The nocturnal BP fall (%) was calculated as (awake SBP − sleep‐time SBP)/awake SBP. We classified the patients\' nocturnal BP fall into the following three patterns: the dipper pattern, if the nocturnal BP fall was higher than 10%; the non‐dipper pattern, if it was between 0% and 10%; and the riser pattern, if it was \<0%. Patients with an extreme dipper pattern (nocturnal BP fall higher than 20%) were combined with those having the dipper pattern for analysis due to the limited number of cases (*n* = 8).

Outcomes {#ehf212500-sec-0008}
--------

The primary endpoints were all‐cause and cardiovascular mortality. Cardiovascular death was defined as death due to HF, myocardial infarction, sudden death, stroke, and vascular disease such as aortic dissection. We checked medical records to determine the vital status and the cause of death. When this information was unavailable in the medical records, we telephoned the patients or their families.

Statistical analysis {#ehf212500-sec-0009}
--------------------

Continuous variables were expressed as mean ± standard deviation or median (interquartile range), and inter‐group differences were compared using Student\'s *t*‐test. Categorical variables were summarized as percentages and analysed using the *χ* ^2^ test. A Cox proportional hazards model was used to investigate the hazard ratio (HR) for all‐cause and cardiovascular deaths. Results were reported as HR, 95% confidence interval (CI), and *P* values. The HR for outcomes in the riser group was compared with that for the non‐riser group, which served as the reference group. JMP version 12 for Windows (SAS Institute Inc., Cary, NC) was used for all statistical analyses. *P* values \<0.05 were considered statistically significant.

Results {#ehf212500-sec-0010}
=======

Baseline characteristics in patients with heart failure with reduced ejection fraction, heart failure with mid‐range ejection fraction, and heart failure with preserved ejection fraction {#ehf212500-sec-0011}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The mean age of all patients with HF registered in the NARA‐HF 3 study was 73.4 ± 12.3 years, and the proportion of female patients was 42.3%. As in previous reports, the proportion of elderly and female patients was as follows: HFpEF \> HFmrEF \> HFrEF (Supporting Information, *Table* [*S1*](#ehf212500-supitem-0001){ref-type="supplementary-material"}). To investigate the differences in ABPM measurements between HFrEF, HFmrEF, and HFpEF, we studied 325 patients who underwent ABPM at discharge. We classified the 325 patients with HF into HFrEF, HFmrEF, and HFpEF groups based on their LVEF and compared their baseline clinical characteristics (Supporting Information, *Table* [*S2*](#ehf212500-supitem-0002){ref-type="supplementary-material"}). The age was younger in the HFrEF group than in the HFmrEF and HFpEF group. The proportion of female patients was higher in the HFpEF group than in the HFrEF group, with the HFmrEF group falling in between. BMI was similar among the three groups. In terms of their echocardiographic data, the LV end‐diastolic diameter and LVEF in the HFmrEF group was also in between the values in the HFrEF and HFpEF groups. Haemoglobin levels was higher in the HFrEF group than in the HFmrEF and HFpEF groups, although sodium was higher and brain natriuretic peptide (BNP) level was lower in the HFpEF group than in the HFmrEF and HFrEF groups. The estimated glomerular filtration rate (eGFR) was higher in the HFrEF group than in the HFpEF group, with the HFmrEF group as the intermediate. The prescription rate of angiotensin‐converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs), beta‐blockers, mineral corticoid receptor antagonists, and diuretics at discharge was higher in the HFrEF group than in the HFpEF group, although the prescription rate of calcium blockers was lower. The rate of the prescription of all drugs for the HFmrEF group was between that of the HFrEF and HFpEF groups.

Differences in vital signs and ambulatory blood pressure monitoring among the heart failure with reduced ejection fraction, heart failure with mid‐range ejection fraction, and heart failure with reduced ejection fraction groups {#ehf212500-sec-0012}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Table* [1](#ehf212500-tbl-0001){ref-type="table"} presents the vital signs and ABPM data of all three groups. At discharge, patients with HFpEF had a significantly higher SBP compared with patients with HFrEF, and patients with HFmrEF were intermediate. However, the DBP and pulse rate at discharge were similar among the three groups.

###### 

Vital signs and ABPM in the HFpEF, HFmrEF, and HFrEF groups

  Characteristic                   HFpEF (n = 130)   HFmrEF (n = 71)   HFrEF (n = 124)   P value
  -------------------------------- ----------------- ----------------- ----------------- ----------
  Vital signs on admission                                                               
  SBP, mmHg                        156.9 ± 39.9      153.0 ± 30.7      141.1 ± 34.0      0.0032
  DBP, mmHg                        85.1 ± 26.8       90.1 ± 21.2       87.2 ± 26.6       0.2614
  Pulse rate, b.p.m.               96.2 ± 29.0       104.9 ± 26.9      105.7 ± 25.5      0.0034
  Vital signs at discharge                                                               
  SBP, mmHg                        116.7 ± 18.1      112.8 ± 17.0      105.1 ± 13.6      \<0.0001
  DBP, mmHg                        62.2 ± 10.1       61.2 ± 9.5        62.2 ± 10.5       0.7801
  Pulse rate, b.p.m.               70.9 ± 12.0       68.8 ± 10.7       71.6 ± 10.8       0.2144
  ABPM                                                                                   
  The average SBP, mmHg                                                                  
  24 h (0:00--24:00)               118.1 ± 18.1      111.5 ± 16.3      101.9 ± 14.1      \<0.0001
  Awake (7:00--20:30)              118.8 ± 17.7      112.0 ± 16.7      102.6 ± 14.1      \<0.0001
  Sleep‐time (22:00--5:00)         115.6 ± 21.4      109.6 ± 16.9      99.8 ± 16.5       \<0.0001
  The average pulse rate, b.p.m.                                                         
  24 h (0:00--24:00)               69.0 ± 8.9        70.5 ± 10.3       70.7 ± 8.3        0.2951
  Awake (7:00--20:30)              69.9 ± 8.9        71.6 ± 9.9        72.0 ± 8.8        0.2203
  Sleep‐time (22:00--5:00)         66.5 ± 12.4       68.3 ± 14.3       66.8 ± 10.3       0.8533
  Pattern of circadian rhythm, %                                                         
  Riser pattern                    21.5              18.3              14.5              0.3451
  Non‐dipper pattern               40.0              43.7              52.4              0.1301
  Dipper pattern                   38.5              38.0              33.1              0.6310
  Nocturnal hypertension, %        43.1              33.8              26.6              0.0217

ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SBP, systolic blood pressure.

With regard to ABPM, the mean 24 h, awake, and sleep‐time SBPs were significantly higher in the HFpEF group than in the HFrEF group, and all SBP measurements in the HFmrEF group were intermediate. In contrast, there was no significant between‐group difference with regard to mean DBP and pulse rate. With respect to the pattern of circadian rhythm, the proportion of patterns was similar among the three groups. The incidence of nocturnal hypertension was higher among patients in the HFpEF group than in the HFrEF group, and that in the HFmrEF group was intermediate.

Prognosis for all patients with acute decompensated heart failure {#ehf212500-sec-0013}
-----------------------------------------------------------------

During the mean follow‐up period of 30.0 months, 112 (34.5%) of all patients with ADHF died, 52 (16.0%) of whom were caused by cardiovascular death. We constructed a univariate Cox proportional hazards model to investigate the HR for all‐cause death among all patients. None of the average SBPs measurements in all categories (24 h, awake, and sleep‐time) were related to all‐cause or cardiovascular death. Moreover, neither nocturnal hypertension nor the circadian rhythm pattern was related to all‐cause or cardiovascular death (*Figure* [*1A*](#ehf212500-fig-0001){ref-type="fig"}).

![(A) Univariate HRs (95% CI) for all‐cause death in all patients. The black squares indicate the HRs for all‐cause death. The solid lines indicate the 95% CI. (B) Univariate HRs (95% CI) for all‐cause death in the HFpEF, HFmrEF, and HFrEF groups. The black rectangles, white triangles, and black diamonds indicate the HRs for all‐cause death in the HFpEF, HFmrEF, and HFrEF groups, respectively. Solid lines indicate the 95% CI. CI, confidence interval; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; SBP, systolic blood pressure.](EHF2-6-1057-g001){#ehf212500-fig-0001}

Differences in prognosis among patients with heart failure with preserved ejection fraction, heart failure with mid‐range ejection fraction, and heart failure with reduced ejection fraction {#ehf212500-sec-0014}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Subsequently, we compared the HR for all‐cause death in the HFpEF, HFmrEF, and HFrEF groups (*Figure* [*1B*](#ehf212500-fig-0001){ref-type="fig"}). The mean SBPs in any category, except for night‐time in the HFrEF group, were not associated with all‐cause death. Nocturnal hypertension or non‐dipper patterns were also not related to all‐cause death in all groups. However, in the HFpEF group, the riser pattern was associated with all‐cause death but not in the HFrEF and HFmrEF groups. Similar results were observed with regard to cardiovascular death.

Comparison between the riser and non‐riser patterns {#ehf212500-sec-0015}
---------------------------------------------------

To further investigate the impact of the riser pattern on the prognosis of patients with ADHF, we divided patients in the HFpEF, HFmrEF, and HFrEF groups into two subgroups, according to their riser or non‐riser pattern (which includes the non‐dipper and dipper patterns).

We compared the baseline clinical characteristics between the riser and non‐riser groups (*Table* [2](#ehf212500-tbl-0002){ref-type="table"}). Age, BMI, the proportion of female patients, and the cause of HF were similar between the two groups across all HF types. The proportions of clinical scenarios were equal between the two groups in all HF types. In terms of laboratory data at discharge, haemoglobin, eGFR, sodium, and BNP levels were similar in the two groups. With regard to antihypertensive drugs at discharge, the proportions of patients treated with ACEis/ARBs, beta‐blockers, diuretics, or calcium blockers were similar in the two groups across all HF types. In the HFpEF group, mineral corticoid receptor antagonists were more frequently administered in the non‐riser group than in the riser group.

###### 

Baseline characteristics in the riser and non‐riser groups

  Characteristic                                              HFpEF            HFmrEF           HFrEF                                                                                 
  ----------------------------------------------------------- ---------------- ---------------- -------- ---------------- ---------------- -------- ---------------- ---------------- --------
  Demographic                                                                                                                                                                         
  Age, years                                                  75.7 ± 11.0      75.9 ± 11.8      0.8368   75.5 ± 11.3      76.6 ± 10.5      0.7355   71.4 ± 12.7      69.0 ± 12.3      0.2542
  Female, %                                                   58.8             50.0             0.3292   50.0             33.3             0.1665   26.5             31.7             0.5472
  BMI, kg/m^2^                                                23.3 ± 3.4       23.6 ± 4.2       0.6677   22.0 ± 3.4       23.6 ± 4.2       0.6677   23.1 ± 3.1       24.1 ± 4.4       0.1221
  Cause of HF, %                                                                                                                                                                      
  Ischaemic                                                   23.8             22.0             0.8174   65.9             51.9             0.2406   43.4             36.6             0.4684
  Valvular                                                    13.8             18.0             0.5166   11.4             11.1             0.9739   8.4              4.9              0.4585
  Dilated cardiomyopathy                                      6.3              4.0              0.5729   15.9             18.5             0.7768   36.1             41.5             0.5668
  Medical history, %                                                                                                                                                                  
  Hypertension                                                77.5             86.0             0.2236   72.7             69.2             0.7550   74.1             85.4             0.1452
  Diabetes mellitus                                           41.8             42.0             0.9796   52.3             40.7             0.3440   38.3             43.9             0.5498
  Dyslipidaemia                                               37.3             48.0             0.2365   53.7             56.0             0.8529   40.0             31.7             0.3688
  Smoking                                                     16.3             22.0             0.4145   39.5             25.9             0.2381   31.7             27.5             0.6334
  Old myocardial infarction                                   22.5             12.0             0.1241   45.5             29.6             0.1815   34.6             26.8             0.3827
  Clinical scenario (CS), %                                                                     0.1701                                     0.3329                                     0.3191
  CS1                                                         62.5             74.0                      63.6             55.6                      44.6             56.1             
  CS2                                                         28.8             24.0                      36.4             40.7                      45.8             31.7             
  CS3                                                         8.8              2.0                       0.0              3.7                       9.6              12.2             
  NYHA class on admission, %                                                                                                                                                          
  III or IV                                                   90.0             84.0             0.3167   88.6             100              0.0251   90.4             90.2             0.9834
  Echocardiographic parameters                                                                                                                                                        
  LVEF, %                                                     63.5 ± 8.2       63.1 ± 6.8       0.7033   44.6 ± 2.9       44.7 ± 2.5       0.9430   29.4 ± 6.8       30.1 ± 6.7       0.5389
  LVEDD, mm                                                   46.4 ± 6.4       47.3 ± 6.0       0.6175   52.6 ± 6.8       53.1 ± 7.1       0.8708   59.7 ± 9.4       62.3 ± 8.7       0.3405
  Laboratory data at discharge                                                                                                                                                        
  Haemoglobin, g/dL                                           11.3 ± 1.9       11.0 ± 1.9       0.2751   11.2 ± 1.7       11.1 ± 1.7       0.6826   12.3 ± 2.0       12.7 ± 2.4       0.3650
  eGFR, mL/min/1.73m^2^                                       40.7 ± 23.2      36.1 ± 22.6      0.3115   45.2 ± 18.9      40.6 ± 15.9      0.3255   47.2 ± 23.2      49.2 ± 27.0      0.8776
  Sodium, mmol/L                                              138.0 ± 3.5      138.8 ± 3.6      0.0993   136.9 ± 3.2      138.0 ± 3.6      0.3467   137.5 ± 3.7      137.8 ± 3.1      0.8259
  Plasma BNP, pg/mL[a](#ehf212500-note-0003){ref-type="fn"}   196 (113--377)   183 (114--345)   0.9765   322 (104--574)   335 (199--697)   0.2469   288 (178--539)   327 (209--513)   0.9498
  Medication at discharge, %                                                                                                                                                          
  ACEi or ARBs                                                77.5             80.0             0.7350   88.4             85.2             0.7002   92.7             97.6             0.2384
  MRAs                                                        37.5             18.0             0.0157   32.6             33.3             0.9464   47.7             51.2             0.7020
  Beta‐blockers                                               61.3             62.0             0.9318   81.4             74.1             0.4707   90.2             92.7             0.6500
  Ca channel blockers                                         41.8             56.0             0.1145   19.1             22.2             0.7499   7.4              2.4              0.2326
  Diuretics                                                   83.8             76.0             0.2797   79.1             92.6             0.1134   89.0             85.4             0.5638

ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; beta‐blocker, beta‐adrenergic receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; Ca, calcium; EDD, end‐diastolic diameter; EF ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure reduced with ejection fraction; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PRA, plasma renin activity.

Data are shown as percentages, means ± standard deviation, or medians (25th and 75th percentile).

The differences in ambulatory blood pressure monitoring between the riser and non‐riser patterns {#ehf212500-sec-0016}
------------------------------------------------------------------------------------------------

*Figure* [*2*](#ehf212500-fig-0002){ref-type="fig"} and *Table* [3](#ehf212500-tbl-0003){ref-type="table"} show the BP profiles during the 24 h of ABPM in the HFpEF, HFmrEF, and HFrEF groups. Sleep‐time SBP was significantly higher in the riser group than in the non‐riser group across all HF types. The elevation of sleep‐time SBP was significantly higher among patients in the HFpEF group than either in the HFrEF or HFmrEF groups. However, the sleep‐time pulse rate was similarly decreased in both the riser and non‐riser groups across all HF types. Consequently, the sleep‐time pulse rate in the riser group was similar to that in the non‐riser group among all patients with HF.

![The SBP and pulse rate profiles over 24 h of ABPM in the HFpEF, HFmrEF, and HFrEF groups. The dotted line is the riser pattern, and the solid line is the non‐riser pattern. CI, confidence interval; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; SBP, systolic blood pressure.](EHF2-6-1057-g002){#ehf212500-fig-0002}

###### 

Vital signs at discharge and ABPM in the riser and non‐riser groups

  Characteristic               HFpEF          HFmrEF         HFrEF                                                                           
  ---------------------------- -------------- -------------- ---------- -------------- -------------- -------- -------------- -------------- ----------
  Vital signs on admission                                                                                                                   
  SBP, mmHg                    154.2 ± 41.0   161.1 ± 38.1   0.3549     154.8 ± 30.8   150.3 ± 30.8   0.4957   140.3 ± 35.2   142.8 ± 31.7   0.5662
  DBP, mmHg                    83.6 ± 25.3    87.5 ± 29.1    0.5092     91.7 ± 20.4    87.5 ± 22.6    0.3522   86.9 ± 28.7    87.9 ± 21.9    0.5412
  Pulse rate, b.p.m.           95.4 ± 28.6    97.5 ± 29.9    0.4481     107.3 ± 27.3   101.0 ± 26.3   0.5339   104.6 ± 23.8   108.0 ± 28.8   0.9259
  Vital signs at discharge                                                                                                                   
  SBP, mmHg                    115.0 ± 17.5   119.4 ± 18.8   0.2435     114.3 ± 17.9   110.2 ± 15.4   0.3370   105.2 ± 13.8   105.0 ± 13.4   0.7249
  DBP, mmHg                    61.1 ± 9.2     64.1 ± 11.3    0.1046     61.8 ± 9.9     60.3 ± 9.0     0.4091   62.1 ± 10.6    62.4 ± 10.4    0.9336
  Pulse rate, b.p.m.           69.5 ± 12.2    73.2 ± 11.5    0.0359     69.0 ± 11.2    68.4 ± 10.1    0.8122   72.3 ± 11.5    70.2 ± 9.1     0.3958
  ABPM                                                                                                                                       
  Average SBP, mmHg                                                                                                                          
  24 h (0:00--24:00)           115.4 ± 17.8   122.5 ± 17.8   0.0171     112.8 ± 17.5   109.3 ± 14.2   0.4344   100.2 ± 13.7   105.4 ± 14.5   0.0422
  Awake (7:00--20:30)          117.8 ± 18.2   120.3 ± 16.8   0.2935     114.8 ± 17.8   107.5 ± 14.0   0.0903   102.0 ± 14.2   103.8 ± 14.1   0.4966
  Sleep‐time (22:00--5:00)     107.6 ± 17.9   128.4 ± 20.4   \<0.0001   106.8 ± 17.5   114.2 ± 15.0   0.0460   94.9 ± 13.8    109.9 ± 17.1   \<0.0001
  Average pulse rate, b.p.m.                                                                                                                 
  24 h (0:00--24:00)           68.6 ± 9.3     69.6 ± 8.3     0.4833     71.4 ± 10.2    69.1 ± 10.6    0.4379   70.6 ± 7.5     70.8 ± 9.8     0.9091
  Awake (7:00--20:30)          69.3 ± 9.3     71.0 ± 8.2     0.2056     72.6 ± 9.5     70.0 ± 10.5    0.1653   72.0 ± 7.9     72.0 ± 10.5    0.8442
  Sleep‐time (22:00--5:00)     66.5 ± 12.7    66.5 ± 12.0    0.9962     69.2 ± 15.7    66.8 ± 11.8    0.8590   66.6 ± 9.8     67.4 ± 11.4    0.9217

ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SBP, systolic blood pressure.

Data shown as mean ± standard deviation.

Prognosis and outcome {#ehf212500-sec-0017}
---------------------

*Figure* [*3*](#ehf212500-fig-0003){ref-type="fig"} shows the Kaplan--Meier survival curves for the HFpEF, HFmrEF, and HFrEF groups. With regard to the HFpEF group, the survival rate was significantly lower in the riser group than in the non‐riser group, for all‐cause death (log‐rank 0.0159; *Figure* [*3A*](#ehf212500-fig-0003){ref-type="fig"}) and cardiovascular death (log‐rank 0.0172; *Figure* [*3B*](#ehf212500-fig-0003){ref-type="fig"}). In contrast, both all‐cause and cardiovascular deaths were similar between the riser group and the non‐riser group in patients with HFmrEF (log‐rank 0.7773 and log‐rank 0.2175; *Figure* [*3C, D*](#ehf212500-fig-0003){ref-type="fig"}) and patients with HFrEF (log‐rank 0.8145 and log‐rank 0.4147; *Figure* [*3E, F*](#ehf212500-fig-0003){ref-type="fig"}).

![Kaplan--Meier event‐free survival curves for (A) all‐cause death and (B) cardiovascular death in patients with HFpEF, (C) all‐cause death and (D) cardiovascular death in patients with HFmrEF, and (E) all‐cause death and (F) cardiovascular death in patients with HFrEF in the riser group (dotted line) compared with the non‐riser group (solid line). HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.](EHF2-6-1057-g003){#ehf212500-fig-0003}

*Table* [4](#ehf212500-tbl-0004){ref-type="table"} shows the unadjusted and adjusted HRs of outcomes for the riser and non‐riser groups. Among patients in the HFpEF group, the unadjusted HRs for all‐cause and cardiovascular deaths were significantly higher in the riser group than in the non‐riser group (HR, 1.97; 95% CI, 1.12--3.49; 0.0187; and HR, 2.60; 95% CI, 1.16--6.06; 0.0206, respectively). Even after adjustment for covariates (age, haemoglobin, eGFR, and BNP at discharge) in the multivariable Cox proportional hazards model, the riser pattern among patients in the HFpEF group remained an independent predictor of all‐cause and cardiovascular deaths (HR, 2.01; 95% CI, 1.12--3.62; 0.0200; and HR, 2.48; 95% CI, 1.08--5.90; 0.0332, respectively).

###### 

Unadjusted and adjusted HRs for adverse outcomes in the riser and non‐riser groups

                           All‐cause death   Cardiovascular death                                    
  ------------------------ ----------------- ---------------------- -------- --- ------------------- --------
  HFpEF                                                                                              
  Unadjusted HR (95% CI)   1                 1.97 (1.12--3.49)      0.0187   1   2.60 (1.16--6.06)   0.0206
  Adjusted HR (95% CI)     1                 2.01 (1.12--3.62)      0.0200   1   2.48 (1.08--5.90)   0.0332
  HFmrEF                                                                                             
  Unadjusted HR (95% CI)   1                 0.89 (0.38--1.96)      0.7763   1   0.28 (0.02--1.68)   0.1850
  Adjusted HR (95% CI)     1                 0.69 (0.28--1.64)      0.4044   1   0.21 (0.01--1.95)   0.2078
  HFrEF                                                                                              
  Unadjusted HR (95% CI)   1                 0.92 (0.45--1.80)      0.8137   1   1.43 (0.58--3.39)   0.4224
  Adjusted HR (95% CI)     1                 1.21 (0.57--2.45)      0.6048   1   2.16 (0.84--5.45)   0.1085

CI, confidence interval; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio.

Data shown as median (25th and 75th percentile). The Cox proportional hazards model adjusted for the following covariates: age, haemoglobin, estimated glomerular filtration rate, and B‐type natriuretic peptide at discharge.

Discussion {#ehf212500-sec-0018}
==========

The present study investigated the 24 h profile of BP and pulse rate in patients with ADHF and demonstrated that the riser pattern is associated with both all‐cause and cardiovascular deaths only in patients with HFpEF but not in those with HFrEF or HFmrEF. The clinical significance of the riser pattern among patients with HFmrEF is closer to that of patients with HFrEF than those of patients with HFpEF, although most baseline characteristics for patients with HFmrEF fall between those for patients with HFrEF and HFpEF.

In earlier studies, high SBP was found to be a predictor of better prognosis among patients with HFrEF and HFpEF.[24](#ehf212500-bib-0024){ref-type="ref"}, [25](#ehf212500-bib-0025){ref-type="ref"} However, our study failed to show an association between average values of 24 h or awake‐time SBP and better outcomes for any type of HF. In the NARA‐HF 3 study, SBP higher than 100 mmHg at discharge was also a predictor of better outcomes among patients with HFrEF but not among those with HFmrEF or HFpEF (data not shown). More interestingly, abnormal 24 h variations of SBP, such as nocturnal hypertension or non‐dipper pattern, which are associated with cardiovascular events among patients with hypertension irrespective of whether they were being treated with antihypertensive drugs[26](#ehf212500-bib-0026){ref-type="ref"}, [27](#ehf212500-bib-0027){ref-type="ref"}, [28](#ehf212500-bib-0028){ref-type="ref"}, were not observed in any of the groups in our study. This indicates that the clinical significance of 24 h BP variation is different between patients with hypertension and those with HF.

The riser pattern was associated with all‐cause and cardiovascular deaths only among patients with HFpEF. This finding is consistent with the earlier report by Komori *et al*.,[16](#ehf212500-bib-0016){ref-type="ref"} in which patients with HF were divided into two groups of patients, HFrEF and HFpEF, and patients with HFmrEF were included in the same group as patients with HFrEF. In accordance with their findings, our results showed that the riser pattern was not associated with outcomes among patients with either HFrEF or HFmrEF. Although the mechanism underlying the association between the riser pattern and a prognosis among patients with HFpEF is currently unclear, it may be related to the fact that hypertension is more closely involved in the aetiology of HFpEF than HFrEF. Because all patients in the current study were receiving medical therapy, the mechanism of the development of the riser pattern should be interpreted with caution. In short, our results could be indicative that sleep‐time SBP is simply not well controlled by the treatment or that the intrinsic pathophysiology of HFpEF is possibly related to the development of the riser pattern. Nevertheless, the pathology of HFpEF is different from that of HFrEF and probably from that of HFmrEF as well.

Although the mechanism of the development of the riser pattern has not been clearly understood yet, it has been suggested that the disturbances in the sympathetic nervous system, the baroreceptor reflex, and volume overload are involved in its development during sleep.[12](#ehf212500-bib-0012){ref-type="ref"} Generally, the changes in pulse rate are also well correlated with the activation of the sympathetic nervous system. However, in this study, the sleep‐time pulse rate was similarly decreased in both the riser and non‐riser groups across all types of HFs, indicative of a decrease in sympathetic nervous activity during sleep in both the riser and non‐riser groups. Therefore, it may be possible that the riser pattern results from a volume overload than being related to sympathetic nervous activity. Considering that the pulse rate in patients with hypertension and the riser pattern is also lower during sleep‐time than during awake‐time,[29](#ehf212500-bib-0029){ref-type="ref"} the development of the riser pattern seems to partly share a common mechanism in HFpEF and hypertension.

While therapeutic strategies with medical and non‐medical treatments have been established in patients with HFrEF,[30](#ehf212500-bib-0030){ref-type="ref"}, [31](#ehf212500-bib-0031){ref-type="ref"}, [32](#ehf212500-bib-0032){ref-type="ref"} no effective therapies for HFpEF has been established. In patients with HFpEF, diuretics, ACEis, and ARBs are recommended to improve symptoms or reduce HF rehospitalization. Given that the riser pattern of SBP was associated with an increased risk of adverse outcomes among patients with HFpEF, the present study may provide a new treatment strategy to attempt to better control the circadian rhythm in patients with HFpEF.

Up to now, the association between HF and sleep‐disordered breathing (SDB) has been reported. Although SDB is broadly classified into two types, obstructive sleep apnoea and central sleep apnoea (CSA), CSA is more often associated with HF.[33](#ehf212500-bib-0033){ref-type="ref"}, [34](#ehf212500-bib-0034){ref-type="ref"}, [35](#ehf212500-bib-0035){ref-type="ref"}, [36](#ehf212500-bib-0036){ref-type="ref"} In SDB, the repeated episodes of apnoea, hypoxia, re‐oxygenation, and arousal throughout the night cause further sympathetic nervous system activation. In actually, the relationship between SDB and nocturnal hypertension has been reported. In our study, it is possible that SDB may affect the riser pattern, but the relationship is unknown because there is no record of respiratory frequency and SpO~2~ during sleep. Moreover, it was reported that continuous positive airway pressure (CPAP) and phrenic nerve stimulation therapy improved BP or the symptoms of patients with HF with CSA,[30](#ehf212500-bib-0030){ref-type="ref"} but no one had used CPAP at the time of ABPM in our study.

Another interesting finding of our present study is that the clinical significance of the riser pattern in patients with HFmrEF is similar to those with HFrEF. The aetiology of HFmrEF is more closely associated with that of HFrEF than with that of HFpEF. For example, the rates of ischaemic and dilated cardiomyopathy were high, while the rate of hypertensive heart disease was low. Moreover, \~40% of patients with HFmrEF and 30% of those with HFrEF had a history of myocardial infarction, but only 18% of patients with HFpEF did. These similarities in aetiology and background between HFmrEF and HFrEF may have influenced the results in this study.

The event rate in this study was slightly higher compared with the recent meta‐analysis.[37](#ehf212500-bib-0037){ref-type="ref"} Although the reason is unclear, it may be affect by lower administration rates of beta‐blockers or higher rate of co‐morbidities, such as hypertension and diabetes mellitus, and lower eGFR.

There are several limitations to this study. First, the analysis in this study was the low power because the sample size was small. In particular, in cardiovascular death, multiple analyses mean that the significance *P* about 0.03 could have been a chance finding. Therefore, a large‐scale prospective study will be necessary to confirm hypothesis in this study. Second, ABPM was performed under medications that have antihypertensive effects, because safety considerations prevented halting their use. Therefore, it was not clear whether the circadian BP rhythm observed in this study was due to self‐regulation, to the effect of the medications, or to both. Third, sleep‐time was pre‐determined based on the hospital hours and not individual patterns because we could not confirm accurate wake‐up time and bedtime for each subject, which might alter the results of the circadian BP rhythm in ABPM, including nocturnal and riser patterns. Fourth, the subject included paroxysmal atrial fibrillation patients, and it is unknown whether or not it was atrial fibrillation rhythm during measurement.

In summary, the riser pattern is associated with an increased risk of adverse outcomes among patients with HFpEF but not in patients with HFrEF or HFmrEF. This finding may be related to the pathology of HFpEF and may help us to develop better treatment strategies.
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